Next Article in Journal
Endogenous Purification of NR4A2 (Nurr1) Identified Poly(ADP-Ribose) Polymerase 1 as a Prime Coregulator in Human Adrenocortical H295R Cells
Next Article in Special Issue
Typical and Atypical Inducers of Lysosomal Cell Death: A Promising Anticancer Strategy
Previous Article in Journal
Human Macrophages Preferentially Infiltrate the Superficial Adipose Tissue
Previous Article in Special Issue
An Interplay between Senescence, Apoptosis and Autophagy in Glioblastoma Multiforme—Role in Pathogenesis and Therapeutic Perspective
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Autophagic Regulation of p62 is Critical for Cancer Therapy

1
Jiangsu Key Laboratory of New Drug Screening & Jiangsu Center for Pharmacodynamics Research and Evaluation, China Pharmaceutical University, Nanjing 210009, China
2
Institute of Translational Medicine & Jiangsu Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Treatment of Senile Diseases, Medical College, Yangzhou University, Yangzhou 225001, China
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2018, 19(5), 1405; https://doi.org/10.3390/ijms19051405
Submission received: 30 March 2018 / Revised: 30 April 2018 / Accepted: 3 May 2018 / Published: 8 May 2018

Abstract

Sequestosome1 (p62/SQSTM 1) is a multidomain protein that interacts with the autophagy machinery as a key adaptor of target cargo. It interacts with phagophores through the LC3-interacting (LIR) domain and with the ubiquitinated protein aggregates through the ubiquitin-associated domain (UBA) domain. It sequesters the target cargo into inclusion bodies by its PB1 domain. This protein is further the central hub that interacts with several key signaling proteins. Emerging evidence implicates p62 in the induction of multiple cellular oncogenic transformations. Indeed, p62 upregulation and/or reduced degradation have been implicated in tumor formation, cancer promotion as well as in resistance to therapy. It has been established that the process of autophagy regulates the levels of p62. Autophagy-dependent apoptotic activity of p62 is recently being reported. It is evident that p62 plays a critical role in both autophagy and apoptosis. Therefore in this review we discuss the role of p62 in autophagy, apoptosis and cancer through its different domains and outline the importance of modulating cellular levels of p62 in cancer therapeutics.
Keywords: p62; PB1; self-oligomerization; autophagy; apoptosis; cancer; therapy p62; PB1; self-oligomerization; autophagy; apoptosis; cancer; therapy
Graphical Abstract

Share and Cite

MDPI and ACS Style

Islam, M.A.; Sooro, M.A.; Zhang, P. Autophagic Regulation of p62 is Critical for Cancer Therapy. Int. J. Mol. Sci. 2018, 19, 1405. https://doi.org/10.3390/ijms19051405

AMA Style

Islam MA, Sooro MA, Zhang P. Autophagic Regulation of p62 is Critical for Cancer Therapy. International Journal of Molecular Sciences. 2018; 19(5):1405. https://doi.org/10.3390/ijms19051405

Chicago/Turabian Style

Islam, Md. Ariful, Mopa Alina Sooro, and Pinghu Zhang. 2018. "Autophagic Regulation of p62 is Critical for Cancer Therapy" International Journal of Molecular Sciences 19, no. 5: 1405. https://doi.org/10.3390/ijms19051405

APA Style

Islam, M. A., Sooro, M. A., & Zhang, P. (2018). Autophagic Regulation of p62 is Critical for Cancer Therapy. International Journal of Molecular Sciences, 19(5), 1405. https://doi.org/10.3390/ijms19051405

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop